NSCLC含铂新辅助化疗后ERCC1和BRCA1表达及其与疗效关系

EXPRESSIONS OF ERCC1 AND BRCA1 AND THEIR RELATIONSHIP WITH CURATIVE EFFECT IN NON-SMALL CELL LUNG CANCER AFTER PLATINUM-BASED NEOADJUVANT CHEMOTHERAPY

目的探讨含铂新辅助化疗对非小细胞肺癌(NSCLC)组织中核苷酸切除修复基因1(ERCC1)和乳癌易感基因1(BRCA1)表达的影响及其与化疗疗效的关系。方法应用免疫组化PV二步法检测50例NSCLC病人含铂新辅助化疗前后ERCC1、BRCA1的表达。结果 ERCC1主要在细胞核表达,细胞浆有少量表达;BRCA1在细胞核表达。含铂新辅助化疗前ERCC1、BRCA1阳性表达率为48.00%、64.00%,化疗后为68.00%、80.00%,化疗前后二者表达强度比较差异有显著性(u=-2.657、-3.083,P<0.01)。ERCC1、BRCA1表达阳性者化疗有效率为41.67%、40.63%,表达阴性者为73.08%、88.89%,两组比较差异有显著性(χ2=5.055、11.016,P<0.05、0.01)。结论含铂新辅助化疗可影响NSCLC组织中ERCC1、BRCA1的表达,从而影响肿瘤对顺铂的敏感性。

Objective To investigate the influence of paltinum-based neoadjuvant chemotherapy（PBNC） on expressions of ERCC1 and BRCA1 in non-small cell lung cancer（NSCLC） and their association with the therapeutic efficacy. Methods The expressions of ERCC1 and BRCA1 were detected immuno-histochemically by PV method in specimens of 50 patients with NSCLC before and after the PBNC. Results The expression of ERCC1 was found mainly in the nucleus,few in cytoplasm;while that of BRCA1 was found in nucleus.The positive expressions of ERCC1 and BRCA1 before the PBNC was 48.00% and 64.00%,respectively,and that after PBNC was 68.00% and 80.00%,the difference of expression potency between before and after PBNC was significant（u=-2.657,-3.083;P〈0.01）.The effective power of the chemotherapy in patients with a positive expression of ERCC1 and BRCA1 was 41.67% and 40.63%,respectively,in those with a negative expression was 73.08% and 88.89%,being a significant difference between the two groups（χ2=5.055,11.016;P〈0.05,0.01）. Conclusion PBNC can influence the expressions of ERCC1 and BRCA1 in NSCLC tissue and thus lead to tumor＇s sensitivity to cisplatin.